World-class
Radiation Oncology
Radiation Oncology
Enquiry Form
Radiation Oncology Highlights
image
01

One of the pioneers of indigenous applicators and separation surgery resulting in minimal tissue damage

image
02

Experienced and trained team of creating internationally accepted protocols

image
03

Among first in India to introduce VMAT (Volumetric arc therapy) on infinity linear accelerator

image
04

Organ specific radiotherapy and radiosurgery

image
05

Use of cutting-edge technologies including Cyberknife VSI robotic system and Tomotherapy

image
06

First in country to establish frameless (SBRT) from Elekta to treat lung and liver tumors in under 20 minutes

About the Speciality

Radiation Oncology at Medanta capitalizes on the team approach that bring together our expert radiation oncologists, dosimetrists, physicists, and nurses for every patient under our care. We use advanced technologies, including Cyberknife VSI, Integrated Brachytherapy Unit, and Image-Guided Radiation Therapy (IGRT) to treat cancers of the bladder, brain, breast, reproductive organs (male and female), lung, and head and neck. Our centre combined conventional radiotherapy and new technologies to treat malignant lymphomas, ocular melanoma and sarcomas.

Our Treatments

Investing expertise, compassion, care to win over cancer

Ailments

Investing expertise, compassion, care to win over cancer

Latest Technology Utilisation

Painless treatments using cutting-edge technologies:

  • Cyberknife
  • Tomotherapy
  • Linear Accelerators
  • Brachytherapy
Cyberknife
Cyberknife
The Cyberknife boasts pain-free and non-invasive cancer treatment, eliminating the need for a traditional surgical approach. It achieves a higher level of precision by utilising two X-ray cameras. Cyberknife is particularly effective in treating various diseases, including oligometastatic disease, brain tumors, prostate cancer, liver cancer, lung cancer, pancreatic cancer, recurrent head and neck cancer, as well as kidney cancer.
Back to top
×

Request Call Back



× Disclaimer Image
×

Share Profile Via